Navigation Links
Roche Molecular Diagnostics Invests $57.5 Million in 'Green' Research Building
Date:4/3/2008

New Facility Meets LEEDS Standards for Sustainable Development

PLEASANTON, Calif., April 3, 2008 /PRNewswire/ -- Roche Molecular Diagnostics (RMD) today announced the opening of its new research facility at the company's global headquarters in Pleasanton, California. The building represents the final phase of consolidation of RMD's West Coast operations into one campus in Pleasanton which now houses close to 500 employees, including 120 members of RMD's research teams previously located in Alameda. RMD is a world-leading molecular diagnostics company, developing diagnostics designed to provide information allowing healthcare providers to select and monitor patient response to therapy or identify molecular characteristics of a disease. RMD's products also help to ensure the safety of blood and blood products before they are used for medical procedures by using its approved systems to screen donations.

RMD is a world-leading molecular diagnostics company, developing diagnostics that provide information to select the best therapy for a particular patient by enabling physicians to monitor response to treatment or identify molecular characteristics of a disease. RMD also supports the safety of the blood supply by using our approved systems to screen donors.

The research building encompasses more than 135,000 square feet on RMD's 33.4 acre campus in the Hacienda Business Park. Designed by a local firm, DES Architects + Engineers under the leadership of Craig Ivancovich, architect and principal, it was then built by another local company, DPR Construction. The building and its surroundings incorporate numerous features designed to ensure successful green building status, construction and operation, and further demonstrate Roche's ongoing commitment to sustained development and environmental efficiency throughout its global operations. Going forward, RMD is working to implement final operational improvements that will enable the new facility to qualify for Leadership in Energy and Environmental Design (LEED) "green building" certification from the US Green Building Council.

"In designing the new building, it was important to us to minimize our environmental footprint while designing a functional space that could support core research functions and state-of-the-art molecular biology research laboratories," said Daniel O'Day, President and CEO. "With the development of this new building, we have achieved these goals while creating an optimal space for our employees to focus on their ongoing contributions to improving healthcare for people around the world."

About RMD

Headquartered in Pleasanton, California, Roche Molecular Diagnostics is the world leader in molecular in vitro diagnostics. A business area of Roche (Basel, Switzerland), RMD develops and manufactures innovative tests based on its Nobel Prize winning polymerase chain reaction (PCR) technology. PCR is the technology that underlies a new generation of medical diagnostics.

RMD supplies a wide array of innovative medical diagnostic products, services, and technologies to researchers, physicians, patients, hospitals and laboratories worldwide. Our marketed diagnostic tests and automated instrument platforms, and those now in development, are focused on blood screening, virology, microbiology, genomics and oncology, and sexually transmitted diseases. For a complete list of our diagnostics and blood screening products, please visit our website at http://molecular.roche.com

About Roche

Headquartered in Basel, Switzerland, Roche is one of the world's leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world's biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people's health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totaled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 79,000 people. Additional information is available on the Internet at http://www.roche.com.

All trademarks used or mentioned in this release are legally protected by law.

For further information please contact:

Amy Berry

Roche Molecular Diagnostics

Communications

Phone: 925-730-8028

email: amy.berry@contractors.roche.com


'/>"/>
SOURCE Roche Molecular Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Roche Joins Forces With Enon Tabernacle Baptist Church to Provide Free Hepatitis C Testing to the Community
2. Roche Extends Tender Offer for Ventana
3. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
4. Roche Real-Time HIV Test is Faster and Less Labor-Intensive Than Competitors
5. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
6. Amarin Announces Publication of Pre-Clinical Memory Data in Journal of Neurochemistry
7. Med Ad News Honors Roche as Company of the Year
8. MacroChem To Participate in PIPEs Conference October 18th and 19th in New York City
9. MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Companys Scientific Advisory Board
10. Phase I Results Announced for R1507 From Genmabs Collaboration With Roche
11. Kosan to Reacquire Epothilone Program From Roche
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/3/2016)... May 3, 2016  Dr. Thomas P. McHugh ... The Woodlands, Texas , now offers ... of treated fat cells in just 25-minutes, leaving a ... 90 percent of Americans report feeling bothered by excess ... reduction procedures are a growing industry. This innovative new ...
(Date:5/2/2016)... Sunnyvale, CA (PRWEB) , ... May 02, 2016 , ... ... visualization solutions today announced the addition of three Secure Remote Desktop modules to its ... the remote desktops from Linux and Unix servers to the user’s PC over encrypted ...
(Date:4/29/2016)... , April 29, 2016 ... Transparency Market Research "Separation Systems for Commercial Biotechnology ... Trends, and Forecast 2015 - 2023", the separation ... US$ 10,665.5 Mn in 2014 and is projected ... 2015 to 2023 to reach US$ 19,227.8 Mn ...
(Date:4/28/2016)... India , April 28, 2016 ... JT, Stirling, and Brayton Cryocoolers), Service (Technical Support, Product ... and Geography - Global Forecast to 2022", published by ... USD 2.94 Billion by 2022, at a CAGR of ... 70 market data Tables and 94 Figures spread through ...
Breaking Biology Technology:
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
(Date:3/15/2016)... ALBANY, New York , March 15, 2016 ... a new market report published by Transparency Market Research "Digital ... Growth, Trends and Forecast 2015 - 2023," the global digital ... at US$ 731.9 Mn in 2014 and is forecast to ... to 2023. Growth of micro, small and medium enterprises (MSMEs) ...
(Date:3/11/2016)... March 11, 2016 --> ... research report "Image Recognition Market by Technology (Pattern Recognition), ... Advertising), by Deployment Type (On-Premises and Cloud), by Industry ... published by MarketsandMarkets, the global market is expected to ... 29.98 Billion by 2020, at a CAGR of 19.1%. ...
Breaking Biology News(10 mins):